Zinplava

Indicated For

Clostridioides difficile infection (CDI) recurrence prevention

About This Medication

# Zinplava Patient Guide: How to Get Zinplava at Low or No Cost **Important Notice: Zinplava (bezlotoxumab) has been discontinued as of January 31, 2025.** This means the medication is no longer manufactured or available through standard channels, including patient assistance programs. If you were previously prescribed Zinplava or are seeking it for recurrent Clostridioides difficile (C. diff) infection prevention, consult your healthcare provider immediately for alternative treatments. This guide provides historical context on Merck's patient assistance programs and next steps. ## About Zinplava Zinplava (bezlotoxumab) was a prescription monoclonal antibody injection administered intravenously to reduce the risk of C. diff infection recurrence in adults 18 years and older who were receiving antibacterial treatment for C. diff and at high risk for recurrence. It was not an antibiotic and did not treat active C. diff infections but helped prevent them from returning when used alongside standard antibiotic therapy.[6][7] Common side effects included nausea, fever, and infusion reactions. In patients with a history of congestive heart failure (CHF), use required careful consideration due to higher rates of heart failure and mortality observed in studies.[7] Given its discontinuation in 2025, no new prescriptions or assistance applications are possible. Merck, the manufacturer, previously offered support through programs like the Merck Patient Assistance Program (PAP) and Merck Access Program, but these are irrelevant for Zinplava post-discontinuation.[1][2][4] ## Who Qualifies for Assistance? Historically, Merck's Patient Assistance Program provided free medicines to eligible individuals, primarily those **without prescription drug or health insurance coverage** who could not afford needed Merck products. Qualification required meeting income criteria and demonstrating financial need.[2][4] Special exceptions were sometimes made for those with insurance under certain financial and medical hardship circumstances, but patients with insurance plans tied to alternative funding programs were ineligible.[2] However, with Zinplava discontinued, **no one qualifies for assistance today**. If you have leftover supplies or prior authorization, contact your doctor or pharmacist. For ongoing C. diff management, discuss alternatives like fecal microbiota transplantation, new antibiotics (e.g., fidaxomicin), or emerging therapies. ## Income Eligibility Breakdown Merck's PAP did not publicly specify exact federal poverty level (FPL) percentages for all products, but eligibility focused on uninsured patients with income meeting program criteria. Exceptions required proof of special financial/medical hardship.[2] Specific thresholds for Zinplava were not detailed, and post-discontinuation, they are moot. For reference, here's a **general table of typical PAP income guidelines** (historical; varies by program): | Household Size | Annual Income Limit (e.g., ~400% FPL, approximate) | |----------------|---------------------------------------------------| | 1 (Individual) | $58,320 | | 2 (Couple) | $78,880 | | 3 | $99,440 | | 4 | $120,000 | *Notes: Actual limits depended on program specifics; higher for Alaska/Hawaii. Always verify with manufacturer. Irrelevant for discontinued Zinplava.*[2] ## Insurance Requirements Merck programs targeted the uninsured. Insured patients might qualify via exceptions for hardship but were excluded if their plan required applying to PAPs as a prerequisite or involved alternative funding vendors.[2][4] Medicare patients could be referred but primarily needed to lack coverage.[4] With discontinuation, insurance coverage is obsolete—check for biosimilar or generic C. diff options via your plan. ## Step-by-Step Application Process **Applications are no longer accepted for Zinplava.** Previously: 1. **Visit MerckHelps.com** or call the Merck Access Program for guidance.[1][4] 2. **Check eligibility** online or via phone (e.g., 888-727-9535 for select products).[2] 3. **Gather documents**: Proof of income, lack of insurance, ID, prescription.[2] 4. **Submit application**: Online, mail, or phone; doctor involvement often needed.[3] 5. **Await approval**: Up to 1 year of free medicine if approved.[2] **Current Action Steps:** Contact your doctor for alternatives. Explore general Merck PAP for other products at merckhelps.com or rxassist.org.[1][3] ## Timeline and Delivery Historical processing took weeks; approved patients received up to 1 year supply, shipped directly or via pharmacy.[2] Zinplava was IV-administered in a healthcare setting, not self-administered.[6] No delivery possible now. ## Alternatives if Denied or Unavailable - **Consult your doctor** for C. diff prevention: Fidaxomicin, vancomycin, or metronidazole; probiotics; FMT.[7] - **Other PAPs**: Search rxassist.org for C. diff drugs.[3] - **Discount cards**: Savings up to 90% at pharmacies for alternatives (not Zinplava).[5] - **Government programs**: Medicaid, Medicare Extra Help, or state assistance. - **No biosimilars** listed for Zinplava.[program details] ## Disclaimer This guide is for informational purposes only and not medical advice. Zinplava's discontinuation as of January 31, 2025, renders assistance unavailable. Always consult healthcare professionals for treatment. Program details can change; Merck reserves rights to modify/discontinue.[2] Information synthesized from historical sources as of 2026; verify current status.

Program information last verified: March 30, 2026